OpenAI · ARM · United Kingdom · BBC Technology
AI cancer cures slowed by chip shortage, confirms UK's biggest tech boss
Compiled by KHAO Editorial — aggregated from 1 source. See llms.txt for citation guidance.
◌ Single Source
The boss of the biggest UK-headquartered tech firm has said that artifical intelligence will find a cure for cancer that humans cannot in their lifetimes.
Key facts
- As the great hope of UK tech for decades, some government ministers have lamented Arm's sale to Japanese investors in 2016 and subsequent partial flotation on New York's Nasdaq rather than in London
- Prof Chris Bakal, from the Institute of Cancer Research, London, and CEO of Sentinal4D, said the real question was no longer whether they use AI, it's what they feed it
- Rene Haas, chief executive of Cambridge-based chip designer Arm Holdings, said while modelling how a DNA marker is impacted by cancer was currently "too complex" a problem, computers are "going
- Earlier this summer, the company's peak share price amid the AI boom made it, in cash terms, the most valuable UK-based company in history
Summary
Rene Haas, chief executive of Cambridge-based chip designer Arm Holdings, said while modelling how a DNA marker is impacted by cancer was currently "too complex" a problem, computers are "going to solve it" in the future. Haas also told the BBC that AI would lead to widespread humanoid robots in the next five years, but that its current rapid growth was being held up by a shortage of chips needed to build data centres. However, he was sceptical about the idea chips could be manufactured in the UK in the future. Arm designs the brains or CPUs of microchips already used in hundreds of billions of phones, cars, smartwatches and gadgets across the globe.